samedan logo
 
 
spacer
home > ict > spring 2017 > needle in a haystack
PUBLICATIONS
International Clinical Trials

Needle in a Haystack

If there is one hot zone in drug development, it is the area of rare diseases. Formerly the province of small biotechnology companies and pharmaceutical startups, this area is now attracting the attention of increasingly bigger players, as most recently exemplified by Shire’s establishment of a separate rare disease innovation hub in Cambridge, Massachusetts, US. As we have moved beyond the blockbuster era, and with the declining productivity of Big Pharma pipelines, many larger firms are looking to rare diseases as a potential alternate revenue stream – hence the increased pace of partnering and acquisition activity, as well as efforts to expand ‘organically’ into the field.

Despite the rush of entrants into the category, conducting clinical trials in this area remains a complex proposition. Much of the difficulty is derived from the fact that many rare diseases are not as well understood as more common ailments like diabetes and hypertension. The relatively small patient populations often do not easily lend themselves to defining efficacy endpoints, inclusion and exclusion criteria or other study design elements. Such a lack of clarity makes it especially difficult to devise a protocol that will meet the FDA’s scrutiny, and could even discourage people from participating.

Incentives and Challenges

Nevertheless, pharmaceutical developers have numerous motivations for conducting these studies, including Prescription Drug User Fee Act waivers, tax credits and extended exclusivity for orphan treatments; these can give companies extra time to recoup trial-associated costs. That said, many start small – initially focusing on indications with small patient populations, which may be a springboard to expanded indications or, if they are lucky, off-label usage.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Scott Treiber, PhD, MBA, is Executive Vice President of Biopharmaceutical Development at Chiltern and oversees all aspects of biopharmaceutical development including Phase 1-4 trials across a wide range of therapeutic areas. Before joining Chiltern, he held Vice President positions at Theorem, inVentiv Health, Hospira and PharmaNet. Scott is on the board of the Center for Healthcare Innovation.
spacer
Scot Treiber
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Aptar Pharma’s Electronic Lockout Device Approved by EMA

Aptar Pharma, a world leader in innovative drug delivery systems, is pleased to announce the approval by the EMA of the first integrated electronic nasal lockout device following a multi-year development with Takeda Pharmaceuticals International AG.
More info >>

White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). It’s about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>

 
Industry Events

Clinical Trial Supply Logistics & Temperature Management Forum

22-24 May 2017, Hotel Del Coronado| San Diego, CA

Ensuring timely distribution and formulating key forecasting methods to avoid clinical trial disruptions. We have gathered the sharpest minds from Eli Lilly, Sunovion Pharmaceuticals, Anthera, Genentech, and many more to optimize inventory processes, package and labeling, multi-vendor management, and new forecasting ideas that demonstrate safety, efficacy, and dosage in your clinical trial supply chain at the: Clinical Trial Supply Logistics & Temperature Management Forum
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement